AFT Pharmaceuticals (ASX:AFP, NZE:AFT) expanded its US licensing agreement with supplier Hikma Pharmaceuticals to include its pain relief medicine Combogesic Rapid, according to a Monday filing with the New Zealand bourse.
Under the deal, Hikma will take over all channels for Combogesic Rapid in the US, the filing said. The companies will also restructure the profit-sharing arrangements for Combogesic IV and tablets to quarterly payments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.